Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series
Authors:
Open Access
- 6 July 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (9) , 1152-1157
Abstract
Background: Clozapine has a unique efficacy profile among individuals suffering from treatment-resistant schizophrenia, but is associated with hematological side effects. The use of granulocyte colony-stimulating factors (G-CSF) to allow clozapine continuation or rechallenge has emerged as a promising option, but evidence is still scarce. Aim: To describe the largest case series so far published regarding this practice. Method: A national clozapine hematological monitoring database was consulted to identify all patients who had had neutrophil count 9/L since 2004 in Quebec and was cross-referenced with hospital pharmacy software to identify patients who had received at least one dose of G-CSF, such as filgrastim, while being exposed to clozapine. All data were collected retrospectively, using patients’ medical files, from January to July 2019. Results: Using G-CSF, three out of eight patients could maintain clozapine despite neutropenia episodes that otherwise would have required treatment discontinuation. The only side effect reported was mild short-lived back pain, over a mean 3-year follow-up period. In all but one case, filgrastim was used on an “as-needed” basis at doses of 300 mcg administered subcutaneously. Conclusion: These results suggest that the “as-needed” use of G-CSF is well-tolerated and may allow clozapine rechallenge in some well-selected patients, adding to the paucity of data regarding long-term safety and efficacy of this strategy. More research may help to better define potential candidates and optimal regimen of such practice.Keywords
Funding Information
- Fonds d’enseignement et de recherche de la Faculté de pharmacie de l’Université Laval
- Santé
- Janssen and Otsuka-Lundbeck Alliance
- Otsuka-Lundbeck Alliance, Janssen, Sunovion, and Mylan
This publication has 24 references indexed in Scilit:
- Clozapine and Granulocyte Colony-Stimulating FactorJournal of Clinical Psychopharmacology, 2007
- Outcome Following Clozapine DiscontinuationThe Journal of Clinical Psychiatry, 2007
- The Effect of Sudden Clozapine Discontinuation on Management of Schizophrenic PatientsThe Journal of Clinical Psychiatry, 2006
- Rechallenge with clozapine following leucopenia or neutropenia during previous therapyThe British Journal of Psychiatry, 2006
- Diurnal variation of neutropenia during clozapine treatmentInternational Journal of Neuropsychopharmacology, 2005
- Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosisInternational Clinical Psychopharmacology, 2003
- Active monitoring of 12760 clozapine recipients in the UK and IrelandThe British Journal of Psychiatry, 1999
- Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadinePsychopharmacology, 1996
- Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United StatesNew England Journal of Medicine, 1993
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981